Clinical observation of lobaplatin combined with IL-2 and thrombin in the treatment of malignant pleural effusion

【Absrtact】 Objective To observe the clinical effect of lobaplatin combined with IL-2 and thrombin in the treatment of malignant pleural effusion. Methods 60 NSCLC patients with malignant pleural effusion were randomly divided into the control group and the trial group,30 cases in each group. All patients were treated with thoracentesis and inserted central venous catheter to drain pleural effusion. After exhaustion of pleural effusion,the control group was treated with lobaplatin by pleural perfusion,and the trial group was treated with IL-2 and thrombin on the base of the control group. The treatment,side effect and quality of life were compared. Results The improvement of KPS score of living quality and controlling pleural effusion was more pronounced in the trial group than in the control group( P 0.05),and the side effect was significant lower in the trial group than the control group( P 0.05). Conclusion Lobaplatin combined with IL-2 and thrombin pleural perfusion has significant curative effect and less side effect in the treatment of NSCLC patients with malignant pleural effusion.